Developing innovative therapies that bring new hope to patients with dilated cardiomyopathy (DCM) — that is the mission of CardioGenix.
Shaping the Future of
Cardiomyopathy
About the CardioGenix DCM Lab
Rewriting the destiny of hereditary cardiomyopathy
CardioGenix LLC is a bioventure founded in April 2026. Established by Sachio Morimoto following his retirement from academia, alongside Naoto Tadano, former Lab Head at Zenyaku Kogyo, the company specializes in developing innovative therapeutics for Dilated Cardiomyopathy (DCM). Driven by our creed, "Restoring Myocardial Power through Science," we address the root pathology of hereditary DCM to deliver hope to patients whose needs remain unmet by existing conventional medical treatments and therapies.
CEO Message
For decades, I have dedicated my academic career to elucidating the pathology of hereditary cardiomyopathy and seeking novel pharmacological treatments. Through research using TNNT2 ΔK210 mutant mouse models, we have demonstrated that reduced myocardial Ca²⁺ sensitivity is the fundamental core of DCM, sharing these findings through numerous peer-reviewed publications.Recognizing the inherent limitations of university research, I founded CardioGenix LLC as a platform to fully leverage my expertise. Utilizing our proprietary DCM model mice and IonOptix technology for simultaneous measurement of cardiomyocyte contraction and Ca²⁺, we are accelerating development toward clinical application in partnership with LTT Bio-Pharma.
Naoto Tadano Co-CEO, MSc
Our Mission
Guided by our goal to restore myocardial strength through science, we target the fundamental pathology of hereditary dilated cardiomyopathy. We are committed to developing life-changing drugs for patients left without options, striving to improve quality of life and provide new therapeutic choices for families affected by genetic DCM.
Company Profile
Company Name: CardioGenix LLC
Representative: Sachio Morimoto
Founded: April 2026
Capital: 9 Million JPY
Location: Fukuoka, Japan (Private)
Business: R&D of Inherited Cardiomyopathy Drugs
Core Tech: Proprietary TNNT2 ΔK210 DCM Mice, IonOptix Cardiomyocyte Ca²⁺ Measurement, Skinned Myofiber Functional Analysis
History:
Until March 2026 Conducted DCM research at Kyushu University and IUHW, Published widely
March 2026 Retired from University Tenure
April 2026 Established CardioGenix LLC
2026–Present Advancing non-clinical trials through ongoing joint research with LTT Bio-Pharma